Description
Tesamorelin is a synthetic growth‑hormone–releasing hormone (GHRH) analog developed to stimulate your pituitary to release growth hormone (GH) in a pulsatile (natural‑style) manner. Unlike taking GH directly, tesamorelin cues your own system to produce GH. In the U.S., tesamorelin (brand Egrifta SV®) is FDA‑approved for reducing visceral abdominal fat (VAT) in adults with HIV‑associated lipodystrophy. Off‑label/body‑composition uses outside that indication are not FDA‑approved.
Note on vial size: “10 mg” refers to the amount of peptide per vial in some research/compounding markets. The FDA‑approved product is supplied as 2 mg single‑use vials reconstituted for 2 mg SC once daily under labeling. Dosing and reconstitution for non‑approved vials vary and should be directed by a clinician.
There are no reviews yet.